T
Theriva Biologics Inc
AMEX:TOVX
Theriva Biologics Inc
AMEX:TOVX
Price:
0.18
USD
Market Cap:
$6.4m
Relative Value
There is not enough data to reliably calculate the relative value of TOVX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TOVX
Relative Value
Base Case
Not Available
Multiples Across Competitors
TOVX Competitors Multiples
Theriva Biologics Inc Competitors
Theriva Biologics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
T
|
Theriva Biologics Inc
AMEX:TOVX
|
6.4m USD | 0 | -0.2 | 0.1 | 0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
403.9B USD | 6.8 | 171.8 | 16.6 | 23.6 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 377 | -2 377 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
205.8B USD | 5.6 | 26.5 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.1B USD | 6.2 | 21.6 | 14.6 | 14.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.6B USD | 10.4 | 31.5 | 24.1 | 25.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD | 5.7 | 18.3 | 13.8 | 15.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR | 14.3 | 33.7 | 57.9 | 59.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.5B AUD | 3.1 | 16.3 | 11.2 | 14 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
